WO2014173058A1 - Protéine polysaccharidique de trametes robiniophila, son procédé de préparation et son application - Google Patents

Protéine polysaccharidique de trametes robiniophila, son procédé de préparation et son application Download PDF

Info

Publication number
WO2014173058A1
WO2014173058A1 PCT/CN2013/082697 CN2013082697W WO2014173058A1 WO 2014173058 A1 WO2014173058 A1 WO 2014173058A1 CN 2013082697 W CN2013082697 W CN 2013082697W WO 2014173058 A1 WO2014173058 A1 WO 2014173058A1
Authority
WO
WIPO (PCT)
Prior art keywords
polysaccharide protein
polysaccharide
volume
preparation
sophora
Prior art date
Application number
PCT/CN2013/082697
Other languages
English (en)
Chinese (zh)
Inventor
徐无为
陆正鑫
Original Assignee
启东盖天力药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 启东盖天力药业有限公司 filed Critical 启东盖天力药业有限公司
Publication of WO2014173058A1 publication Critical patent/WO2014173058A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/375—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Basidiomycetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to a polysaccharide protein of cockroach and a preparation method and use thereof. Background technique
  • the industrial production of mycelium was realized, and the extracts of the ear fungus (the fermented material of the ear fungus) were used as raw materials to develop medicines such as the ear granules and the glutinous granules, which satisfied the clinical drug demand.
  • the present invention provides a polysaccharide protein of the ear and a preparation method and use thereof.
  • the present invention provides a polysaccharide protein of the ear (also referred to as "the ear polysaccharide egg of the present invention” White”), the monosaccharide composition of the polysaccharide protein is fucose, arabinose, galactose, glucose, xylose and mannose, and the mass ratio thereof is 0.1: 1.0: 5.4: 4.4: 2.1: 7.0.
  • the weight average molecular weight proteoglycans 7.0xl0 5 -2.0xl0 6 Da, preferably 1.69xl0 6 Da.
  • the method for preparing the polysaccharide protein comprises the following steps:
  • step (2) adding the saccharide moiety obtained in the step (1) to anhydrous ethanol to form a sugar solution having an alcohol concentration of 55% to 70% by volume, preferably 60% by volume, and centrifuging to obtain a precipitate;
  • the extract of the ear fungus includes an aqueous extract of the fungus, particularly a hot water (60-100 ° C) extract.
  • the aqueous extract of the ear fungus can be used as it is or after concentration.
  • the concentrated aqueous extract of the ear fungus (i.e., the ear cream) or the water extract of the unconcentrated ear fungus can be prepared or purchased by a conventional method.
  • the method for preparing the polysaccharide protein further comprises the step of subjecting the product obtained by eluting the NaCl solution to dialysis and desalting.
  • the method for preparing the polysaccharide protein further comprises the step of separating and purifying the product after dialysis and desalting using a Sepharose CL-6B agarose gel column.
  • the present invention provides a method for preparing the above polysaccharide protein, which comprises the following steps:
  • step (2) adding the saccharide moiety obtained in the step (1) to anhydrous ethanol to form a sugar solution having an alcohol concentration of 55% to 70% by volume, preferably 60% by volume, and centrifuging to obtain a precipitate;
  • the preparation method further comprises the step of dialysis and desalting of the product eluted with the aqueous solution of NaCl.
  • the preparation method further comprises the step of separating and purifying the dialysis and desalted product using a Sepharose CL-6B agarose gel column.
  • the preparation method comprises the following steps:
  • step (3) The inner part of the bag collected in step (3) was separated by DEAE-52 ion exchange column chromatography, eluted with lO Mol/LNaCl solution, and the eluted part was concentrated and dialyzed to remove salt.
  • the dialysis process was Dialysis dialysis for three days, dialysis for two days; and
  • step (4) The product obtained in the step (4) was separated and purified using a Sepharose CL-6B agarose gel column until it was detected as a pure product by high performance liquid chromatography.
  • the present invention provides the use of the above polysaccharide protein for the preparation of a medicament for treating a tumor.
  • the polysaccharide protein of the present invention has remarkable antitumor activity and is expected to be an active ingredient of a novel antitumor drug.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an agaric acid protein and a pharmaceutically acceptable carrier, wherein the composition comprises 0.01% to 99.5% by weight of a polysaccharide protein as an active ingredient, and
  • the auricular polysaccharide protein contains 90% by weight to 100% by weight of the polysaccharide protein of the first aspect of the present invention, based on the total weight of the polysaccharide protein of the ear.
  • the pharmaceutical composition preferably contains 0.1% to 99.9% by weight of the polysaccharide protein as an active ingredient, preferably 0.1% to 99.5% by weight of the polysaccharide protein as an active ingredient, more preferably a weight ratio. It is 0.5%-95% active ingredient.
  • the pharmaceutical composition comprising a therapeutically effective amount of the polysaccharide protein of the present invention, has significant antitumor efficacy.
  • the mixture of the polysaccharide protein of the ear and the pharmaceutically acceptable carrier, diluent and the like can be orally administered in the form of a tablet, a capsule, a granule, a powder or a syrup or in the form of an injection. Oral administration.
  • the above formulations can be prepared by conventional pharmaceutical methods.
  • useful pharmaceutically acceptable carriers include excipients (e.g., saccharide derivatives such as lactose, sucrose, Portuguese) Glucose, mannitol and sorbitol; starch derivatives such as corn starch, potato starch, dextrin and carboxymethyl starch; cellulose derivatives such as crystalline cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, carboxy Methylcellulose calcium, sodium carboxymethylcellulose; gum arabic; dextran; silicate derivatives such as magnesium aluminum metasilicate; phosphate derivatives such as calcium phosphate; carbonate derivatives such as calcium carbonate; Such as calcium sulfate, etc.), binders (such as gelatin, polyvinylpyrrolidone and polyethylene glycol), disintegrants (such as cellulose derivatives such as sodium carboxymethylcellulose, polyvinylpyrrolidone), lubricants (for example Talc, calcium stearate, magnesium stearate, cetyl, boric acid,
  • a safe and effective amount of the polysaccharide protein of the invention is administered to a mammal, wherein the safe and effective amount is usually at least about 1 microgram per day, and in most cases no more than about 10 milligrams per kilogram of body weight. .
  • the dosage is from about 1 microgram per day to about 3 milligrams per kilogram of body weight.
  • specific doses should also take into account factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled physician.
  • polysaccharide protein of the present invention can be used as a single drug or in combination with other drugs.
  • Preferred combinations include: in combination with surgery, in combination with one or more western medicines, in combination with Chinese herbal medicines, in combination with radiation therapy.
  • the administration route of the pharmaceutical composition of the present invention is not particularly limited, and includes, but is not limited to, oral administration, injection administration, intratumoral administration, implantation administration, intraluminal administration, anal administration, transdermal administration.
  • Administration, internal and external application; preferred injection administration includes: intravenous injection, intramuscular injection, subcutaneous injection, intraluminal injection, intratumoral administration.
  • the present invention has at least the following beneficial effects:
  • the present invention uses a system of water extraction, alcohol precipitation, deproteinization, dialysis small molecule, ion exchange chromatography and gel molecular size exclusion chromatography to obtain a uniform polysaccharide protein component from the fungus of the fungus, and Comprehensive application of molecular weight analysis, monosaccharide composition and amino acid composition analysis, infrared spectrum analysis and methylation analysis, etc., confirmed the chemical structure characteristics, and defined its weight average molecular weight, monosaccharide composition and ratio, amino acid composition and The ratio, and the way in which the sugar residues are attached.
  • Such a polysaccharide component with clear structure and uniform molecular weight is an ideal molecular model for studying the active constituents and biological activities of polysaccharides from Auricularia auricula, in order to elucidate the immunomodulatory and antitumor active components of Auricularia auricula polysaccharides and their effects.
  • the mechanism lays a foundation, and the present invention will provide a scientific basis for the further development and utilization of the fungus and the quality control of related preparations.
  • Figure 1 is a flow chart of the alcohol precipitation of the ear extract of the ear fungus
  • Fig. 2 is a flow chart of purification of TCP-60 column chromatography by 60% ethanol precipitation site of the ear fungus extract of the ear fungus;
  • Figure 3 is a standard curve for determining the molecular weight (Mw) of polysaccharide protein TP-3;
  • Figure 4 is an ion chromatogram of a reference solution in the analysis of the monosaccharide component of the polysaccharide protein TP-3;
  • Figure 5 is a UPLC-GPC chromatogram of the polysaccharide protein TP-3;
  • Figure 6 is an ion chromatogram of the composition analysis of the polysaccharide of TP-3;
  • Fig. 7 shows the proliferation of mouse spleen cells by 3 H-TdR incorporation method, wherein: TCP: crude polysaccharide; TP-1: polysaccharide protein-1; TP-2: polysaccharide protein-2; TP-3: Polysaccharide protein-3; TP-4: polysaccharide protein-4; To-1: low molecular weight component-1; ⁇ -2: low molecular weight component-2; ⁇ -3: ⁇ ears Low molecular weight component-3; ⁇ -4: ⁇ ear low molecular weight component-4; TFP: ⁇ ear coarse total protein fraction;
  • Figure 8 shows the proliferation of T and sputum lymphocytes in mice by 3 H-TdR incorporation, wherein Figure ⁇ is CD19+ cells; Figure B is CD3+ cells; Figure C is mouse T lymphocytes; Figure D is mouse B lymphocytes Cell; Dex: dextran; TCP: crude polysaccharide; TP-1: polysaccharide protein-1; TP-2: polysaccharide protein-2; TP-3: polysaccharide protein-3; TP-4: Polysaccharide protein-4; LPS: lipopolysaccharide;
  • Fig. 9 shows changes in the proportion of T and sputum lymphocytes in mice and humans after stimulation with polysaccharides from the ear, wherein Fig. B is mouse lymphocytes; Fig. B is mouse B lymphocytes; Fig. C is human T lymphocytes; For human B lymphocytes; Dex: Dextran; TCP: crude polysaccharide; TP-1: Polysaccharide protein-1; TP-2: Polysaccharide protein-2; TP-3: Polysaccharide protein -3; TP-4: polysaccharide protein-4; LPS: lipopolysaccharide;
  • Figure 10 shows the expression of CD69 on the surface of T and sputum lymphocytes after stimulation with polysaccharides from Auricularia auricula.
  • Fig. B shows the expression of CD69 on the surface of T lymphocytes stimulated by polysaccharides from Auricularia auricula
  • Figure B shows the expression of CD69 on the surface of B lymphocytes after stimulation with Auricularia auricula.
  • Dex Dextran
  • TCP crude polysaccharide
  • TP-1 Polysaccharide protein-1
  • TP-2 Polysaccharide protein-2
  • TP-3 Polysaccharide protein-3
  • TP- 4 polysaccharide protein-4
  • LPS lipopolysaccharide
  • Figure 11 shows changes in NO release in mouse peritoneal macrophages after stimulation with polysaccharides from Lycium barbarum L., Dex: Dextran; TCP: crude polysaccharide; TP-1: Polysaccharide protein-1; TP-2: Polysaccharide protein-2; TP-3: polysaccharide protein-3; TP-4: polysaccharide protein-4; To-1: low molecular weight component-1; To-2: low molecular weight component -2; ⁇ -3: ⁇ ear low molecular weight component-3; ⁇ -4: ⁇ ear low molecular weight component-4; TFP: ⁇ ear coarse total protein fraction; LPS: lipopolysaccharide; Figure 12 ⁇ ear polysaccharide protein Inhibition of tumor angiogenesis endothelial cell proliferation, TP-3: Auricularia Polysaccharide-3. detailed description
  • Example 1 Method for separating and purifying polysaccharide protein of cockroach ( ⁇ -3)
  • the dialysis process was dialysis dialysis for three days, and the distilled water was dialyzed for two days. Then, each section was separated and purified by Sepharose CL-6B agarose gel column until it was pure by high performance liquid chromatography. After the above column chromatography, it was separated from TCP-40 ion exchange column by 0.1 Mol/L. Purification of the eluted fraction of NaCl obtained UPLC (Ultra High Performance Liquid Chromatography) as a homogeneous component of the polysaccharide protein TP-1 (397 mg) and a homogeneous polysaccharide protein TP-2 (1212 mg) from the 0.5 Mol/L NaCl elution site. ), the separation flow chart is shown in Figure 2.
  • UPLC Ultra High Performance Liquid Chromatography
  • the dialysis process was dialysis dialysis for three days, and the dialysis water was dialyzed for two days. Then, each section was separated and purified by Sepharose CL-6B agarose gel column until it was pure by high performance liquid chromatography. After the above column chromatography, it was separated from TCP-60 ion exchange column by 1.0 Mol/L. Purification of the eluted fraction of NaCl resulted in a UPLC (Ultra High Performance Liquid Chromatography) verification of the homogeneous component of the polysaccharide protein TP-3 (1. 21 g).
  • UPLC Ultra High Performance Liquid Chromatography
  • Sample solution preparation Weigh a certain amount of the polysaccharide protein TP-3 prepared in Example 1, add appropriate amount of deionized water, prepare it into a solution with a concentration of lmg/ml, Millipore 0.22 ⁇ water filter to filter, injection detection . 2, monosaccharide composition analysis
  • Instrument configuration and chromatographic conditions Dionex ICS 3000 ion color language, CarboPac PA20 analytical column, 150 x 3mm, S/N 002823, CarboPac PA20 guard column, 50*3mm, S/N 002652, eluent composition and flow rate l- 25 min, Im Mol/L KOH; 25.1-32 min, 30 m Mol/L KOH,; 32.1-35 min, Im Mol/L KOH; 0.45 mL/min, 10 L injection.
  • Preparation of the reference solution Take the appropriate amount of fucose, arabinose, galactose, glucose, xylose, mannose reference substance, dissolve it into 10.0 mg/L of the reference solution with deionized water, shake it, that is, .
  • Standard curve preparation Accurately draw the appropriate amount of reference stock solution, and dilute it with deionized water to 0.5 mg/L, lmg/L, 5 mg/L, 10 mg/L, 15 mg/L standard solution, 0.45 After filtration through ⁇ microporous membrane, the chromatographic conditions were determined by ion chromatography.
  • the peak area integral value is plotted on the ordinate (Y) and each standard concentration is plotted on the abscissa (X).
  • the standard curve of each reference is plotted and the regression equation is calculated. The results are shown in Table 1 and Figure 4.
  • Test article Solution preparation The polysaccharide peptone-3 completely acid hydrolyzate prepared in Example 1 was redissolved in 50 ml of deionized water, sonicated for 10 minutes to dissolve, and the solution was taken in an appropriate amount. The pore size of 0.22 ⁇ water filtration membrane and DIONEX RP II solid phase extraction were performed. Small column. Separately draw the reference solution and the test solution for each ⁇ , and inject them into the ion chromatograph.
  • Partially methylated Aldiol acetyl ester preparation The sample which has been completely methylated is dissolved in 3 mL of 90% by volume of formic acid solution, sealed, depolymerized at 100 °C for 6 h, and added to the reaction flask 2 ⁇ 3 mL of methanol, concentrated and evaporated to dryness under reduced pressure at 40 ° C. The above operation was repeated three times to remove excess formic acid, and then 4 mL of 2 Mol/LTFA solution was added to the depolymerized sample, sealed and hydrolyzed at 110 ° C for 2 h.
  • the solution in the bottle was evaporated to dryness under reduced pressure at 40 ° C, and then 2 to 3 mL of methanol was added thereto, and evaporated to dryness.
  • the above operation was repeated several times to remove excess TFA.
  • the sample treated above was placed in a P 2 0 5 vacuum desiccator and dried under reduced pressure for one day.
  • Temperament conditions are: starting temperature 50 ° C, temperature program 40 ° C / min, to 215 ° C, hold 40 min, detector temperature 250 ° C, DB-5 capillary GC-MS column detection.
  • TP-3 is a dark brown powdery substance, soluble in water, DMSO, insoluble in high concentrations of organic solvents such as methanol and ethanol.
  • the UPLC-GPC-ESLD pattern of the polysaccharide protein presents a symmetrical narrow The chromatographic peak indicates that it is a pure polysaccharide protein material compared with the molecular weight standard.
  • the molecular weight of the polysaccharide protein is 1.69 ⁇ 10 6 Da (see Figure 3), the Lowry reaction is positive, and the UV scan has a weak absorption at 280 nm, indicating This substance contains protein.
  • the polysaccharide protein TP-3 contains six monosaccharides, namely fucose, arabinose, galactose, glucose, xylose and mannose. Among them, the content of mannose and galactose is the highest, followed by glucose, xylose, arabinose and fucose.
  • TP-3 was methylated by Needs method, and after three methylation, it was depolymerized with 90% formic acid to 2 Mol/LTFA complete acid. Hydrolysis, reduction of NaBH 4 and acetylation of acetic anhydride to prepare an alcohol derivative of alditol, and GC-MS analysis was carried out, and the results are shown in Table 3.
  • the 1,3,6-linked galactose methylation analysis showed that the structure of the polysaccharide protein-3 was very complicated. Containing 14 different linked sugar residues, wherein the arabinose is linked to other sugar residues by the 1st, 1st, 3rd, and 1,5th hydroxyl groups, and the xylose is at the 1st and 1st and 4th hydroxyl groups. Other sugar residues form a glycosidic linkage, and fucose is only linked to other sugar residues by the 1,3 hydroxyl group.
  • the mannose is 1,4, 1, 3, 1, 3, and 6
  • the hydroxyl group is linked to other sugar residues to form a glycosidic bond.
  • the glucose is linked to the other sugar residue by a hydroxyl group at the 1st, 1st, 4th positions.
  • the galactose passes through the 1st position, 1, 6th position, 1, 3, and 6 positions.
  • the hydroxyl group is linked to other sugar residues to form a glycosidic bond.
  • ⁇ is provided by Qidong Gaitian Pharmaceutical Co., Ltd. Crude polysaccharide TCP, homopolysaccharide TP-1, TP-2, TP-3, TP-4, low molecular weight components ⁇ -1, ⁇ -2, ⁇ -3, ⁇ -4 were prepared by Example 1.
  • the components of the ear cream (the crude polysaccharide TCP; the polysaccharides TP-1, TP-2, TP-3, TP-4; low molecular weight components ⁇ -1, ⁇ -2, ⁇ -3, ⁇ -4; total free protein fraction (TFP) and negative control drug dextran (Dextran) were co-cultured with mouse spleen cells. After 42 h, 3 H-TdR was spiked, and 48 h later, the cell harvester Filtermate harvester was used to detect it. Proliferation index. The result is shown in Figure 7.
  • the polysaccharide components extracted from the ear cream can stimulate mice. Splenocyte proliferation; low molecular weight components can not stimulate spleen cell proliferation except TO-3.
  • Auricular polysaccharide can stimulate mouse B cell proliferation, but not T cells
  • RESULTS Mouse peritoneal macrophages were cultured in vitro, and crude polysaccharide TCP, ear polysaccharide TP-1,
  • TP-2, ⁇ -3, ⁇ -4, low molecular weight components ⁇ -1, ⁇ -2, ⁇ -3, ⁇ -4, ⁇ ⁇ coarse total free protein part TFP and control polysaccharide dextran (Dextran), Lipopolysaccharide (LPS) was co-cultured, and after 48 hours, the content of NO in the cell culture supernatant was measured using a Griess Reagent kit, and the results are shown in Fig. 11.
  • TP-3 Ear polysaccharide protein-3
  • Polysaccharide protein-3 (TP-3) has a significant inhibitory effect on the proliferation of tumor vascular endothelial cells.
  • the results are shown in Figure 12. The values in the figure are shown as mean ⁇ standard deviation.
  • Each drug-administered group was compared with the control group, and analyzed by analysis of variance and post hoc T test. *P ⁇ 0.05, indicating a significant difference between the two groups. **P ⁇ 0.01, indicating a significant difference between the two groups. ***P ⁇ 0.001, indicating a significant difference between the two groups.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur une protéine polysaccharidique de Trametes robiniophila. Les monosaccharides composant la protéine polysaccharidique sont le fucose, l'arabinose, le galactose, le glucose, le xylose et le mannose, leur proportion en masse est de 0,1:1,0:5,4:4,4:2,1:7,0, et la masse moléculaire moyenne en masse de la protéine polysaccharidique est de 7,0x105-2,0x106Da, et de préférence est de 1,69x106Da. La protéine polysaccharidique de la présente invention peut être utilisée pour préparer un médicament pour la guérison d'une tumeur.
PCT/CN2013/082697 2013-04-24 2013-08-30 Protéine polysaccharidique de trametes robiniophila, son procédé de préparation et son application WO2014173058A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310145106.6A CN104119427B (zh) 2013-04-24 2013-04-24 一种槐耳多糖蛋白及其制备方法和用途
CN201310145106.6 2013-04-24

Publications (1)

Publication Number Publication Date
WO2014173058A1 true WO2014173058A1 (fr) 2014-10-30

Family

ID=51765087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/082697 WO2014173058A1 (fr) 2013-04-24 2013-08-30 Protéine polysaccharidique de trametes robiniophila, son procédé de préparation et son application

Country Status (2)

Country Link
CN (1) CN104119427B (fr)
WO (1) WO2014173058A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114085296A (zh) * 2021-11-02 2022-02-25 浙江中医药大学 一种具有免疫增强作用的血红栓菌均一多糖及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104592372A (zh) * 2015-01-19 2015-05-06 河南科技大学 一种悬浮培养发菜糖蛋白的制备方法
CN116217649B (zh) * 2022-12-30 2024-05-17 中国科学院沈阳应用生态研究所 槐耳中甾体类化合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101204405A (zh) * 2006-12-22 2008-06-25 启东盖天力药业有限公司 槐耳菌质提取物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102621260B (zh) * 2011-01-31 2015-03-25 启东盖天力药业有限公司 一种槐耳菌质提取物的鉴定及检测方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101204405A (zh) * 2006-12-22 2008-06-25 启东盖天力药业有限公司 槐耳菌质提取物及其制备方法和用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUO, YUEWEI ET AL.: "Separation and Analysis of Polysaccharide from the Hyphae of Trametes Robiniophila", CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS, 1993, pages 56 - 60 *
GUO, YUEWEI ET AL.: "Studies on the Constituents of Polysaccharide from the Hyphae of Tramctes Robiniophila(II)-Identification of Polysaccharide from the Hyphae of Trametes Robiniophila and Determination of Its Molar Ratio", JOURNAL OF CHINA PHARMACEUTICAL UNIVERSITY, vol. 23, no. 3, 1992, pages 155 - 157 *
PROGRESS IN MEDICINAL CHEMISTRY., May 2012 (2012-05-01), 8, PENG, SIXUN, BEIJING, pages 197 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114085296A (zh) * 2021-11-02 2022-02-25 浙江中医药大学 一种具有免疫增强作用的血红栓菌均一多糖及其应用
CN114085296B (zh) * 2021-11-02 2023-02-28 浙江中医药大学 一种具有免疫增强作用的血红栓菌均一多糖及其应用

Also Published As

Publication number Publication date
CN104119427A (zh) 2014-10-29
CN104119427B (zh) 2018-03-30

Similar Documents

Publication Publication Date Title
Ru et al. Structural characterization, hypoglycemic effects and mechanism of a novel polysaccharide from Tetrastigma hemsleyanum Diels et Gilg
WO2015090180A1 (fr) Arab-galactane de fleur sanchi, procédé de préparation et utilisation
WO2013139111A1 (fr) Extrait de flavone total d'abelmoschus manihot et son procédé de préparation
CN111234044B (zh) 一种低分子量金耳葡糖醛酸-木甘聚糖及其制备方法和应用
CN107011453B (zh) 一种维药恰麻古多糖及其提取方法和应用
WO2014173058A1 (fr) Protéine polysaccharidique de trametes robiniophila, son procédé de préparation et son application
CN108392485B (zh) 硫酸化甘露葡萄糖醛酸寡糖在制备治疗或预防神经退行性疾病药物中的应用
WO2014173059A1 (fr) Protéine polysaccharidique de trametes robiniophila, son procédé de préparation et son application
WO2014173057A1 (fr) Proteine de polysaccharide de trametes robiniophila, son procede de preparation et application associee
US20140178427A1 (en) Total polysaccharides of radix isatidis and their fractions, and uses thereof as vaccine adjuvants
CN115746156B (zh) 一种具有免疫调节功能的枸杞多糖及其制备方法
WO2014173056A1 (fr) Protéine polysaccharidique de trametes robiniophila, son procédé de préparation et son application
CN114957497B (zh) 一种滇龙胆酸性多糖及其制备方法与应用
CN113480674B (zh) 一种黑茶多糖-ⅰ活性成分及其制备方法和在抗癌中应用
AU686161B2 (en) Remitting agent for nephrotic syndrome and hepatopathy symptoms
CN113402624B (zh) 胞外多糖及其制备方法和应用
CN108752498B (zh) 一种具有增强免疫活性的返魂草多糖及其制备方法与应用
CN108948223B (zh) 桃金娘多糖p1及其分离方法和在制备降血脂药物中的应用
CN107556401B (zh) 一种苦参多糖、其制备方法及保肝和免疫调节用途
CN111748045B (zh) 亨氏马尾藻岩藻聚糖硫酸酯制备方法及应用
CN115028752B (zh) 一种均一的水溶性多糖及其制备方法和应用
CN111620963B (zh) 一种多糖及其制备方法和应用
CN115558035B (zh) 一种具有免疫调节活性的天麻多糖
CN110894244B (zh) 一种土鳖虫多糖的结构及其用途
CN114085296B (zh) 一种具有免疫增强作用的血红栓菌均一多糖及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13883102

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13883102

Country of ref document: EP

Kind code of ref document: A1